MARKET

CRMD

CRMD

CORMEDIX
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.02
-5.98
-39.87%
After Hours: 8.86 -0.16 -1.77% 18:19 03/01 EST
OPEN
8.25
PREV CLOSE
15.00
HIGH
10.49
LOW
8.00
VOLUME
10.80M
TURNOVER
--
52 WEEK HIGH
18.80
52 WEEK LOW
2.160
MARKET CAP
289.84M
P/E (TTM)
-11.4540
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
DJ CorMedix Down Over 41%, on Pace for Record Percent Decrease -- Data Talk
Dow Jones · 3h ago
Mid-Afternoon Market Update: Crud Oil Down Over 1%; Morphic Shares Spike Higher
Toward the end of trading Monday, the Dow traded up 2.25% to 31,626.83 while the NASDAQ rose 2.84% to 13,567.56. The S&P also rose, gaining 2.57% to 3,909.17.
Benzinga · 3h ago
SOS, MNKD, CAN and OTRK among midday movers
Gainers: Morphic (MORF) +106%.Aemetis (AMTX) +58%.SOS (SOS) +43%.Canaan (CAN) +41%.electroCore (ECOR) +37%.Vector Acquisition (VACQU) +37%.The9 (NCTY) +36%.One Stop Systems (OSS) +30%.HCI Group (HCI) +29%.ZK International (ZKIN) +27%.Losers: Athenex (ATNX)...
Seekingalpha · 5h ago
Mid-Day Market Update: Dow Jumps Over 600 Points; CorMedix Shares Plummet
Midway through trading Monday, the Dow traded up 2.09% to 31,580.33 while the NASDAQ rose 2.56% to 13,530.07. The S&P also rose, gaining 2.28% to 3,897.96.
Benzinga · 6h ago
Morphic, electroCore leads healthcare gainers; Athenex, Ontrak among major losers
Gainers: Morphic MORF +104%, electroCore ECOR +51%, Apollo Endosurgery APEN +24%, ASLAN Pharmaceuticals ASLN +23%, Satsuma Pharmaceuticals STSA +19%.Losers: Athenex ATNX -51%, Ontrak OTRK -48%, CorMedix CRMD -39%, Nabriva Therapeutics NBRV -19%, Lixte Biot...
Seekingalpha · 7h ago
Mid-Morning Market Update: Markets Open Higher; Johnson & Johnson Receives FDA Approval For COVID-19 Vaccine
Following the market opening Monday, the Dow traded up 1.91% to 31,522.98 while the NASDAQ rose 1.72% to 13,419.71. The S&P also rose, gaining 1.75% to 3,877.99.
Benzinga · 8h ago
DJ CorMedix: FDA Can't Approve DefenCath NDA in Present Form
Dow Jones · 9h ago
CorMedix shares crash on FDA's DefenCath complete response letter
CorMedix (CRMD) shares plummet 50% premarket after announcing that the U.S. FDA has declined to approve its DefenCath catheter lock solution, citing concerns at its third-party manufacturing facility.FDA, in its complete response letter,
Seekingalpha · 9h ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CRMD. Analyze the recent business situations of CORMEDIX through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CRMD stock price target is 25.60 with a high estimate of 35.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 99
Institutional Holdings: 10.42M
% Owned: 32.42%
Shares Outstanding: 32.13M
TypeInstitutionsShares
Increased
29
811.37K
New
20
157.06K
Decreased
11
34.15K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.07%
Pharmaceuticals & Medical Research
+1.39%
Key Executives
Chairman/Independent Director
Myron Kaplan
Chief Executive Officer/Chief Accounting Officer/Director
Khoso Baluch
Chief Financial Officer/Executive Vice President
Matt David
Chief Financial Officer/Executive Vice President
Matthew David
Executive Vice President/General Counsel
Phoebe Mounts
Executive Vice President
John Armstrong
Executive Vice President
Elizabeth Masson
Director
Paulo Costa
Director
Gregory Duncan
Independent Director
Janet Dillione
Independent Director
Alan Dunton
Independent Director
Steven Lefkowitz
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About CRMD
CorMedix Inc. is a commercial pharmaceutical and medical device company. The Company in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications. Neutrolin is an anti-infective solution for the prevention of catheter-related infections and thrombosis in the central venous catheter markets, such as dialysis, critical care and oncology. Neutrolin is a broad-spectrum antimicrobial/antifungal and anticoagulant combination that is active against common microbes, including antibiotic-resistant strains, and may prevent biofilm formation.

Webull offers kinds of CorMedix Inc. stock information, including NASDAQ:CRMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRMD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CRMD stock methods without spending real money on the virtual paper trading platform.